Cargando…

Potential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of Anxiety

Anxiety disorders are among the most prevalent psychiatric diseases with high personal costs and a remarkable socio-economic burden. However, current treatment of anxiety is far from satisfactory. Novel pharmacological targets have emerged in the recent years, and attention has focused on the endoca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marco, Eva M., Rapino, Cinzia, Caprioli, Antonio, Borsini, Franco, Laviola, Giovanni, Maccarrone, Mauro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567375/ https://www.ncbi.nlm.nih.gov/pubmed/26360704 http://dx.doi.org/10.1371/journal.pone.0137034

Ejemplares similares

Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors
por: Bedse, Gaurav, et al.
Publicado: (2018)

FAAH inhibitors in the limelight, but regrettably
por: Mallet, Christophe, et al.
Publicado: (2016)

The endocannabinoid hydrolase FAAH is an allosteric enzyme
por: Dainese, Enrico, et al.
Publicado: (2020)

Author Correction: The endocannabinoid hydrolase FAAH is an allosteric enzyme
por: Dainese, Enrico, et al.
Publicado: (2020)

Endocannabinoid Regulation of Acute and Protracted Nicotine Withdrawal: Effect of FAAH Inhibition
por: Cippitelli, Andrea, et al.
Publicado: (2011)

Activity of FAAH-Inhibitor JZP327A in an Experimental Rat Model of Migraine
por: Greco, Rosaria, et al.
Publicado: (2023)

Identifying FAAH Inhibitors as New Therapeutic Options for the Treatment of Chronic Pain through Drug Repurposing
por: Zanfirescu, Anca, et al.
Publicado: (2021)

Beyond the Canonical Endocannabinoid System. A Screening of PPAR Ligands as FAAH Inhibitors
por: Brunetti, Leonardo, et al.
Publicado: (2020)

Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases—focusing on FAAH/MAGL inhibitors
por: Ren, Si-yu, et al.
Publicado: (2020)

Analgesic effects of FAAH inhibitor in the insular cortex of nerve-injured rats
por: Jee Kim, Min, et al.
Publicado: (2018)

Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization
por: Grieco, Maddalena, et al.
Publicado: (2021)

FAAH selectively influences placebo effects
por: Peciña, M., et al.
Publicado: (2013)

Neuroprotection by (Endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases
por: Rapino, Cinzia, et al.
Publicado: (2018)

Molecular Basis for Non-Covalent, Non-Competitive FAAH Inhibition
por: Morgillo, Carmine Marco, et al.
Publicado: (2022)

Metabolism and disposition of MM-433593, a selective FAAH-1 inhibitor, in monkeys
por: Banijamali, Ali R, et al.
Publicado: (2014)

A polymorphism in the gene of the endocannabinoid-degrading enzyme FAAH (FAAH C385A) is associated with emotional–motivational reactivity
por: Conzelmann, Annette, et al.
Publicado: (2012)

The FAAH Inhibitor URB597 Modulates Lipid Mediators in the Brain of Rats with Spontaneous Hypertension
por: Biernacki, Michał, et al.
Publicado: (2020)

Hexafluoroisopropyl Carbamates as Selective MAGL and Dual MAGL/FAAH Inhibitors: Biochemical and Physicochemical Properties
por: Barth, Maximilian, et al.
Publicado: (2022)

A catalytically silent FAAH-1 variant drives anandamide transport in neurons
por: Fu, Jin, et al.
Publicado: (2011)

Role of FAAH-Like Anandamide Transporter in Anandamide Inactivation
por: Leung, KwanNok, et al.
Publicado: (2013)

Redox system and phospholipid metabolism in the kidney of hypertensive rats after FAAH inhibitor URB597 administration
por: Biernacki, Michał, et al.
Publicado: (2017)

N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors
por: Sunduru, Naresh, et al.
Publicado: (2017)

Molecular basis of FAAH-OUT-associated human pain insensitivity
por: Mikaeili, Hajar, et al.
Publicado: (2023)

FAAH inhibition ameliorates breast cancer in a murine model
por: Tripathy, Mallika, et al.
Publicado: (2023)

The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition
por: Palermo, Giulia, et al.
Publicado: (2015)

The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents
por: Griebel, Guy, et al.
Publicado: (2018)

The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity
por: Colangeli, Roberto, et al.
Publicado: (2017)

FAAH genetic variation enhances fronto-amygdala function in mouse and human
por: Dincheva, Iva, et al.
Publicado: (2015)

A Swath Label-Free Proteomics insight into the Faah(−/−) Mouse Liver
por: Hamid, Zeeshan, et al.
Publicado: (2018)

FAAH genotype, CRFR1 genotype, and cortisol interact to predict anxiety in an aging, rural Hispanic population: A Project FRONTIER study
por: Harris, Breanna N., et al.
Publicado: (2019)

Potential Therapeutic Value of the STING Inhibitors
por: Zhang, Shangran, et al.
Publicado: (2023)

Modulation of Type-1 and Type-2 Cannabinoid Receptors by Saffron in a Rat Model of Retinal Neurodegeneration
por: Maccarone, Rita, et al.
Publicado: (2016)

The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action
por: Hamtiaux, Laurie, et al.
Publicado: (2012)

Docking-Based 3D-QSAR Studies for 1,3,4-oxadiazol-2-one Derivatives as FAAH Inhibitors
por: Zięba, Agata, et al.
Publicado: (2021)

Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain
por: Della Pietra, Adriana, et al.
Publicado: (2023)

Novel Associations between FAAH Genetic Variants and Postoperative Central Opioid related Adverse Effects
por: Sadhasivam, Senthilkumar, et al.
Publicado: (2015)

Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer’s disease
por: Brunetti, Leonardo, et al.
Publicado: (2019)

The endocannabinoid gene faah2a modulates stress-associated behavior in zebrafish
por: Krug, Randall G., et al.
Publicado: (2018)

FAAH and CNR1 Polymorphisms in the Endocannabinoid System and Alcohol-Related Sleep Quality
por: Soundararajan, Soundarya, et al.
Publicado: (2021)

FAAH rs324420 Polymorphism Is Associated with Performance in Elite Rink-Hockey Players
por: Silva, Hugo-Henrique, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_97ffplm3dgmral3lknb6pjug1s